0001213900-24-023477.txt : 20240318 0001213900-24-023477.hdr.sgml : 20240318 20240318160143 ACCESSION NUMBER: 0001213900-24-023477 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240318 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240318 DATE AS OF CHANGE: 20240318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Augmedix, Inc. CENTRAL INDEX KEY: 0001769804 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 833299164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40890 FILM NUMBER: 24758917 BUSINESS ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 561-989-2208 MAIL ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Malo Holdings Corp DATE OF NAME CHANGE: 20190305 8-K 1 ea0201954-8k_augmedix.htm CURRENT REPORT
false 0001769804 0001769804 2024-03-18 2024-03-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 18, 2024

 

 

 

AUGMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40890   83-3299164

(State or other jurisdiction

of incorporation)

  

(Commission File Number)

  

(I.R.S. Employer

Identification No.)

 

111 Sutter Street, Suite 1300, San Francisco, California 94104

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (888) 669-4885

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.0001 par value per share   AUGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On March 18, 2024, Augmedix, Inc., a Delaware corporation (the “Company”), released its financial results for the fourth quarter and fiscal year ended December 31, 2023. The press release announcing the release of financial results is furnished as Exhibit 99.1 and is incorporated herein by reference.

 

The information provided in this Item 2.02, including Exhibit 99.1, is intended to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		   Description
   
99.1   Press release dated March 18, 2024 announcing fourth quarter and fiscal year 2023 financial results.
     
104   Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AUGMEDIX, INC.
     
Dated: March 18, 2024 By: /s/ Paul Ginocchio
    Paul Ginocchio
    Chief Financial Officer

 

 

2

 

 

 EX-99.1 2 ea020195401ex99-1_augmedix.htm PRESS RELEASE DATED MARCH 18, 2024 ANNOUNCING FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS

Exhibit 99.1

 

 

Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023

 

SAN FRANCISCO, March 18, 2024 — Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three and 12 months ended December 31, 2023.

 

“The fourth quarter was a solid end to a strong year for Augmedix both operationally and financially,” stated Augmedix CEO Manny Krakaris. “We delivered a 45% increase in revenue to $12.7 million, ahead of our most recent guidance, driven by a 44% increase in clinicians in service and net revenue retention of 152%. Additionally, we made steady progress toward our profitability goals by increasing gross profit by 54% to $6.2 million, a margin expansion of 300 basis points to 49.3%, which contributed to the reduction in our operating cash burn.”

 

“We are pleased with the early performance of Augmedix Go, our clinician-controlled mobile app that uses ambient AI technology and structured data to create a fully automated draft medical note,” continued Krakaris. “Feedback has been encouraging in terms of quality and acceptance by clinicians. Initial orders for the ambulatory version since it was made generally available in December have met our expectations. Meanwhile, the emergency room version of Augmedix Go is on track for its own General Availability release by the end of March. Independently, our strategic partner HCA Healthcare is making plans for a broad roll-out across its network of hospitals.”

 

Concluded Krakaris, “With expanded capital resources, we are accelerating our efforts to capture the growing medical documentation opportunity in front of us. We are highly confident that our broad portfolio of products, including a high-performing automated documentation solution, that works effectively across ambulatory and acute care settings, structured data, a bi-directional communication channel to the point of care, and HITRUST certification, provide Augmedix with a differentiated offering that will enable Augmedix to be one of the market leaders as the market matures over the coming years. In 2024, we anticipate another year of strong growth and continued gross margin expansion that will benefit from our increased investment from our November capital raise proceeds.”

 

   Quarter Ended December 31,   Year Ended December 31, 
   2023   2022   Change   2023   2022   Change 
Financial Highlights:                        
Revenues  $12,680   $8,751    45%  $44,855   $30,933    45%
Gross profit  $6,245   $4,049    54%  $21,526   $13,954    54%
Gross margin   49.3%   46.3%   300 bps    48.0%   45.1%   290 bps 
Net loss  $(4,492)  $(5,599)   20%  $(19,171)  $(24,449)   22%
Loss per share  $(0.09)  $(0.15)   40%  $(0.44)  $(0.65)   32%
Adjusted EBITDA (non-GAAP)  $(3,306)  $(4,470)   26%  $(15,210)  $(19,404)   22%

 

 

 

 

 

Fourth Quarter 2023 Financial Highlights

 

All comparisons, unless otherwise noted, are to the three months ended December 31, 2022.

 

●Total revenue was $12.7 million, slightly stronger than our January pre-announcement and an increase of 45% compared to $8.8 million.

 

●Dollar-based Net Revenue Retention was 152% for our Health Enterprise customers compared to 126%.

 

●Gross Profit increased 54% to $6.2 million from $4.0 million.

 

●Gross Margin increased 300 basis points to 49.3% compared to 46.3%.

 

●Operating Expenses were $10.6 million compared to $9.5 million. Adjusted operating expenses, a Non-GAAP metric, increased 12% to $9.9 million compared to $8.8 million.

 

●Net loss was $4.5 million compared to $5.6 million.

 

●Adjusted EBITDA loss, a Non-GAAP metric, improved to $3.3 million from $4.5 million.

 

●Operating cash burn improved to $0.9 million compared to $4.4 million.

 

●Cash and cash equivalents as of December 31, 2023, was $46.2 million compared to $21.3 million as of December 31, 2022.

 

●Common shares and pre-funded warrants outstanding as of December 31, 2023 were 52,988,987. The pre-funded warrants are included in the weighted average shares outstanding for the EPS calculation. Net exercising 100% of the remaining warrants and 100% of the fully-vested and in-the-money employee equity awards at a price of $3.20 per share would add another approximately 4.1 million common shares.

 

Full Year 2023 Financial Highlights

 

All comparisons, unless otherwise noted, are to the 12 months ended December 31, 2022.

 

●Total revenue was $44.9 million, an increase of 45% compared to $30.9 million.

 

●Dollar-based Net Revenue Retention was 148% for our Health Enterprise customers compared to 128%.

 

●Gross Profit increased 54% to $21.5 million from $14.0 million.

 

●Gross Margin increased 290 basis points to 48.0% compared to 45.1%.

 

●Operating Expenses were $40.3 million compared to $36.3 million. Adjusted operating expenses, a Non-GAAP metric, grew 11% to $38.0 million compared to $34.3 million.

 

●Net loss was $19.2 million compared to $24.4 million.

 

●Adjusted EBITDA loss, a Non-GAAP metric, improved to $15.2 million from $19.4 million.

 

Adjusted operating expenses and Adjusted EBITDA are Non-GAAP financial measures. See “Non-GAAP Financial Measures.” Please see “Non-GAAP Financial Measures” below and the Reconciliation of GAAP to Non-GAAP Metrics table below.

 

2

 

 

 

2024 Revenue Guidance

 

Based on the solid finish to 2023 and the trends we are seeing this year, Augmedix expects to generate approximately $60 to $62 million of revenue in 2024.

 

Conference Call

 

Augmedix will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT today, Monday, March 18, 2024, to discuss its fourth quarter and full year 2023 financial results. The conference call can be accessed by dialing + 1-877-407-3982 for U.S. participants or +1 (201) 493-6780 for international participants and referencing conference ID # 13726968. Interested parties may access a live and archived webcast on the “Investor Relations” section of the Company’s website at: ir.augmedix.com.

 

Definition of Key Metrics

 

Average Clinicians in Service: We define a clinician in service as an individual doctor, nurse practitioner or other healthcare professional using our products. We average the month-end number of clinicians in service for all months in the measurement period and the number of clinicians in service at the end of the month immediately preceding the measurement period. We believe growth in the average number of clinicians in service is a key indicator of the performance of our business as it demonstrates our ability to penetrate the market and grow our business.

 

Average Annual Revenue Per Clinician: Average revenue per clinician is determined as total revenue, excluding Data Services revenue, recognized during the period presented divided by the average number of clinicians in service during that same period. Using the number of clinicians in service at the end of each month, we derive an average number of clinicians in service for the periods presented. The average annual revenue per clinician will vary based upon minimum hours of service requested by clinicians, pricing, and our product mix.

 

Dollar-Based Net Revenue Retention: We define a “Health Enterprise” as a company or network of doctors that has at least 50 clinicians currently employed or affiliated that could utilize our services. Dollar-based net revenue retention is determined as the revenue from Health Enterprises as of twelve months prior to such period end as compared to revenue from these same Health Enterprises as of the current period end, or current period revenue. Current period revenue includes any expansion or new products and is net of contraction or churn over the trailing twelve months but excludes revenue from new Health Enterprises in the current period. We believe growth in dollar-based net revenue retention is a key indicator of the performance of our business as it demonstrates our ability to increase revenue across our existing customer base through expansion of users and products, as well as our ability to retain existing customers.

 

About Augmedix

 

Augmedix (Nasdaq: AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.

 

The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decision support.

 

Incorporating data from millions of interactions across all care settings, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes.

 

Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.

 

Non-GAAP Financial Measures

 

To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: adjusted operating expenses, and adjusted EBITDA. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

 

3

 

 

 

We define Adjusted Operating Expense as total operating expenses less share-based compensation expense.

 

In the fourth quarter of 2023, Augmedix changed its computation of Adjusted EBITDA to better reflect the performance of the Company’s business predominantly due to the equity financing that occurred in November of 2023, which significantly increased the Company’s cash balance. We now define Adjusted EBITDA as net income (loss) adjusted to exclude depreciation and amortization; share-based compensation expense; income tax expense (benefit); and other income (expense) net, which consists of interest expense on our debt facility, interest income from our cash and cash equivalents, realized foreign currency gains and losses, loss on extinguishment of debt, change in fair value of a warrant liability, and grant income from the Bangladesh government related to our Bangladesh subsidiary. Prior to the fourth quarter of 2023, the Company did not exclude interest income earned on cash balances, realized foreign currency transaction gains or losses or grant income received from the Bangladesh government from the computation of Adjusted EBITDA. Adjusted EBITDA has been recast in prior periods to reflect this change for consistency in presentation.

 

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results. We believe that both management and investors benefit from reviewing these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance and liquidity as well as comparisons to our competitors’ operating results. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business.

 

There are a number of limitations related to the use of non-GAAP financial measures. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures and evaluating these non-GAAP financial measures together with their relevant financial measures in accordance with GAAP.

 

For more information on the non-GAAP financial measures, please see the Reconciliation of GAAP to non-GAAP Metrics table in this press release. This accompanying table includes details on the GAAP financial measures that are most directly comparable to Non-GAAP financial measures and the related reconciliations between these financial measures.

 

4

 

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” that involve a number of risks and uncertainties. Words such as “believes,” “may,” “will,” “estimates,” “potential,” “continues,” “anticipates,” “intends,” “expects,” “could,” “would,” “projects,” “plans,” “targets,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the encouraging feedback we have received regarding the early performance of Augmedix Go; the emergency room version of Augmedix Go being on track for its own General Availability release by the end of March; our strategic partner HCA Healthcare is making plans for a broad roll-out across its network of hospitals; the acceleration of our efforts to capture the growing medical documentation opportunity in front of us; our high confidence that our broad portfolio of products, including a high-performing automated documentation solution, that works effectively across ambulatory and acute care settings, structured data, a bi-directional communication channel to the point of care, and HITRUST certification, provide Augmedix with a differentiated offering that will enable Augmedix to be one of the market leaders as the market matures over the coming years; our anticipation that 2024 will be another year of strong growth and continued gross margin expansion that will benefit from the increased investment we are making from our November capital raise proceeds; and our expectation to generate approximately $60 to 62 million of revenue in 2024. Forward-looking statements are based on management’s expectations as of the date of this filing and are subject to a number of risks, uncertainties and assumptions, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our most recent Form 10-K filed with the Securities and Exchange Commission on April 17, 2023 as well as other documents that may be filed by us from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward looking statements: our expectations regarding changes in regulatory requirements; our ability to interoperate with the electronic health record systems of our customers; our reliance on vendors; our ability to attract and retain key personnel; the competition to attract and retain remote documentation specialists; anticipated trends, growth rates, and challenges in our business and in the markets in which we operate; our ability to further penetrate our existing customer base; our ability to protect and enforce our intellectual property protection and the scope and duration of such protection; developments and projections relating to our competitors and our industry, including competing dictation software providers, third-party, non-real time medical note generators and real time medical note documentation services; and the impact of current and future laws and regulations; Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

 

Investors:

 

Matt Chesler, CFA

FNK IR

investors@augmedix.com

 

Media:

 

Kaila Grafeman

Augmedix

pr@augmedix.com

 

5

 

 

 

AUGMEDIX, INC.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except shares and key metrics)

 

   Quarter Ended December 31,   Year Ended December 31, 
   2023   2022   2023   2022 
Revenues  $12,680   $8,751   $44,855   $30,933 
Cost of revenues   6,434    4,702    23,329    16,979 
Gross profit   6,246    4,049    21,526    13,954 
Operating expenses:                    
General and administrative   4,906    4,538    18,442    16,893 
Sales and marketing   2,747    2,339    10,687    9,283 
Research and development   2,940    2,612    11,176    10,149 
Total operating expenses   10,593    9,489    40,305    36,325 
Loss from operations   (4,347)   (5,440)   (18,779)   (22,371)
Other income (expenses):                    
Interest expense   (645)   (373)   (2,253)   (1,675)
Interest income   384    177    1,110    245 
Loss on debt extinguishment   —    —    —    (1,097)
Change in fair value of warrant liability   —    —    (105)   — 
Other   93    108    1,001    560 
Total other income (expenses), net   (168)   (88)   (247)   (1,967)
Loss before income taxes   (4,515)   (5,528)   (19,026)   (24,338)
Income tax expense (benefit)   (24)   71    145    111 
Net loss  $(4,491)  $(5,599)  $(19,171)  $(24,449)
                     
Weighted average shares of common stock outstanding, basic and diluted   49,021,095    37,435,000    43,946,263    37,418,463 
                     
Key Metrics:                    
Average clinicians in service   1,789    1,246    1,585    1,093 
Average annual revenue per clinician   28,200    27,500    28,100    27,900 
Dollar-based net revenue retention   152%   126%   148%   128%

 

6

 

 

 

AUGMEDIX, INC.

Condensed Consolidated Balance Sheet

(Unaudited, in thousands)

 

   December 31, 
   2023   2022 
Assets        
Current assets:        
Cash and cash equivalents  $46,217   $21,251 
Restricted cash   125    125 
Accounts receivable, net of allowance for doubtful accounts of $110 and $102 at December 31, 2023 and 2022, respectively   8,572    6,354 
Prepaid expenses and other current assets   1,909    1,820 
Total current assets   56,823    29,550 
Property and equipment, net   3,739    1,573 
Operating lease right of use asset   5,220    1,567 
Restricted cash, non-current   —    612 
Deposits and other assets   930    339 
Total assets  $66,712   $33,641 
           
Liabilities, and Stockholders’ Equity          
Current liabilities:          
Loan payable, current portion  $5,000   $3,750 
Accounts payable   721    1,563 
Accrued expenses and other current liabilities   6,589    5,321 
Deferred revenue   8,963    7,254 
Operating lease liability, current portion   1,494    872 
Customer deposits   851    554 
Total current liabilities   23,618    19,314 
Loan payable, net of current portion   15,303    11,384 
Other liabilities   421    509 
Operating lease liability, net of current portion   4,049    968 
Total liabilities  $43,391   $32,175 
Total stockholders’ equity   23,321    1,466 
Total liabilities and stockholders’ equity  $66,712   $33,641 

 

7

 

 

 

AUGMEDIX, INC.

Condensed Consolidated Statement of Cash Flows

(Unaudited, in thousands)

 

   Year Ended
December 31,		 
   2023   2022 
Net cash used in operating activities  $(15,400)  $(16,773)
Net cash used in investing activities   (3,146)   (1,408)
Net cash provided by (used in) financing activities   43,370    (1,237)
Effect of exchange rate changes on cash and restricted cash   (470)   (181)
Net increase (decrease) in cash and restricted cash   24,354    (19,599)
Cash and restricted cash at beginning of year   21,988    41,587 
Cash and restricted cash at end of year  $46,342   $21,988 

 

8

 

 

 

AUGMEDIX, INC.

Reconciliation of GAAP to Non-GAAP Metrics

(Unaudited, in thousands)

 

   Quarter Ended December 31,   Year Ended December 31, 
Adjusted EBITDA:  2023   2022   2023   2022 
Net loss  $(4,492)  $(5,599)  $(19,171)  $(24,449)
Add: Other income (expense) , net   169    89    247    1,967 
Add: Depreciation   306    249    1,098    856 
Add: Share-based compensation   736    720    2,471    2,112 
Add: Income tax expense (benefit)   (24)   71    145    111 
Total adjustments   1,186    1,129    3,961    5,045 
Adjusted EBITDA  $(3,306)  $(4,470)  $(15,210)  $(19,404)
                     
Adjusted Operating Expenses:                    
Total operating expenses  $10,593   $9,489   $40,305   $36,325 
Less: Share-based compensation   698    697    2,346    2,023 
Adjusted operating expenses  $9,895   $8,792   $37,959   $34,302 

 

 

9

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 augx-20240318.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 augx-20240318_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 augx-20240318_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 18, 2024
Entity File Number 001-40890
Entity Registrant Name AUGMEDIX, INC.
Entity Central Index Key 0001769804
Entity Tax Identification Number 83-3299164
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 111 Sutter Street
Entity Address, Address Line Two Suite 1300
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code (888)
Local Phone Number 669-4885
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AUGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://augmedix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports augx-20240318.xsd augx-20240318_lab.xml augx-20240318_pre.xml ea0201954-8k_augmedix.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0201954-8k_augmedix.htm": { "nsprefix": "AUGX", "nsuri": "http://augmedix.com/20240318", "dts": { "schema": { "local": [ "augx-20240318.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "augx-20240318_lab.xml" ] }, "presentationLink": { "local": [ "augx-20240318_pre.xml" ] }, "inline": { "local": [ "ea0201954-8k_augmedix.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://augmedix.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201954-8k_augmedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201954-8k_augmedix.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-023477-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-023477-xbrl.zip M4$L#!!0 ( #6 "TR,#(T,#,Q."YX M],_T'U:\;B;8%=A%PDON[7//\'_O@5\*.: MUC\GY.=K(L.D?H?I\7AZ1(,>F;2OY!T!?%OI?WG(0C:E/X(0(WT93+8L4U]> MWJ3F<#%TJY6*Y[[<=[HISLJ C802]KH.[IV>GKJIMX"6D$E?T$*ZYAIW'TN8 M*6LOV8(G3"K,_"5\H&:$17#=S9Q+4+(6>IQ!20$-8 4GP7>&?.QJA\97:P4P MEO80XV@&'F#93T5SQQ)8"E4&:N,JR%;3".1::.9:(ESV;E]F6!P/0PA(8GK2 MH(XJ->]$3Q:%$)BZX2*\A@&.J4[D=XPI&1 (+*2P&((R328C[,,;:D6G8L:X M;F@]5;G%V**(Z(Z=&;3)W'!#< K?=>K(+/1$K0]AG.X5UZ^"A4C0LK+E@E@A M%\" ,)*&SB?(0[:9E]B4J9'&3IA(M!>H(!2@>P85JE94EBGD KMXT$#%J6/O3$+N[S MER[;T:U40$R$+0.8WM'J2>6!"PDL_))*Z8'0(CP"H8CNYX57($N=*$-_7 B# M3!QI(?1P3S3?9*8G\!^212\ Y+8\):OBR\WP^QYFU.YRUF MNI<'-8'/8Z;$=)]&6*04F\-N8_[MW^TB"GQV">;OP*%A#^B"C>?L@7^/;O"&G*&?"","9UQ\C[YANE5;^%5"B4 SOGFF)".R MH-CQ&?K[T?1XA<;C ?5^(RSFXNO]O*KW,T[/)Y/7U]8CQ%_S*Q5-Z%/'- ML H7&+'T;)GHZR4NUM*7$7H""FEY -LUVFCKC)HXMKL'1$)CR_9^UR;T9[LR^^.R/Z'!M3CG3=A MR3-,WV6^'NG<]@UYWQ$_Q+D_TG*<)^\[TK7(_XOMK&WYS8?7?ERIVG@M/S4L MDETF)S 2:Y.JBHX1.-]#/C&4=5>U\ZA1+U6C.1?MMJN9,:\S)='1FK],8I+( MNJP8Q@"]ZZ&_T[8Y%UC%04 SQ"$X6]2#4!7EB:,+QK:8WI-G+KKP M:)SPMVUW\ M5.)@$3(=#J0H#T,JSA-)M=L0/0RUE*[I :R:W!BRH(BQ>P-9*>0HU_N'Y)+% M@Q"I='X ,6S:\2A% <+1=-:'AE3[!.,J22-,"R]70-4#S-0)I[N9KM9$6%I7%OB MB@W(G&;"+ ^"!<"4R4 A0TJ'"J&7GM=W"5BF'F($FV/*W!)@-]FDH*D)B 2K M,8"&@S9_IM0+$3,Y,@E,YRPFNY_)'FQ72^>6"FQW60&$ >$3K=#@" 9A)I1/D&:LXB+9UY[W&'&MW( W,]X M#*]0>J+<0C6H"4VT.D," FR(3P"S1NB'XID4Q-5[/'D%2-7@A;B+.)8'*BW_ MN4X8.0;;;]6ZI:O#;I,IBS @DF!W #^E\H/^@%0,NF6A0#-]0U.G_J&9#H5F M&C0TT_= LWSE@4!S\H:FGOB'YF0H-"=!0W/R+FADQWL=:V;RXZU8\E?;P]F@ MT@LR;:M68 ZR\'!I>>N#106H]8P*\8E)OK"Z%7>"OR0L@I?,D-P+,(!I*S6& M-CQT[ ;[^*D6Q#K.ZUA3+,I[OR1:YF>4:9JT#S&%)CQ(FL9Z!Y="[1.).YYF MF/X[>>X\$;>+O>!A-6R%I*$,#Q6;O3Y@BA@D@WR<6)>XJAL:UE?)C')WKP!; M;!U> :X5!@&!S5'[%>#BZDDABY#N<[3U7B582*U M#]^U,F;+2OO\MB>&P1TKGJY MTZ;N<:LHB-[O($V2R%ZHBT"=;"Q)M MY?RX/YZNEDE&;2>7;8FS.0DP5\U(1GD0; "F3!;R,L0?T/'TKZN_(1WEN/MO M^%)@E3QVL=^L. 6R3UE5KB#HL*@YL$B"0 'V9=)PPU$I18761W:JAEE+FN;Q0&T>DV1ZTO?Z.O/0WYE[OH49HBP L)=IGKH=]FTAS^ZYH@$.@P MUCHI*:5(:WV\D'"8LM;]BX"UMT7 NF<1L YQ$; >N@A8>UL$Z-T6*4+DN'2[ MHLD: \D).]6NH>BP;/)AD0:%"NP/'#.J$'2(<9W1,D]QIM+SBTV^_ROYP=)* M0.8J89A%":95>D3; M%?'^$&>T##1?@=.C#X.A829;.!5A.I=A%7A(=>GZ4GKQ ,9OA-*?&7]E"X)3 MSDA<7$NQW2GJUKM]8J;'=O.A&4 T"ZR1U2+K.)WA\ &0G+' MKVMWFC;>VK9J V*FTR#T#G>9\^.P-BZB/+UBF1'U>Q')"_F",UQZ ]L+R5V_ M5-EEVGR;TJ8-"*%.@^#[DU6,2A6#-5/>4L:(F5QJK7G'4^*&RGWBF);%=NZ8 M2A(0'C9?'1ED!-):+RPL-IC2S]LT822%)R)#Y98%J\4F"PU)0"S8? $LY%*D MM5Y8N-P0L9;3VT^"OV:/97Y6L&V VBT;G9:;C%BE ;'2Y0]@1H>@(D:GU/4# MS^Z04+S(L@BWU")UC UHUF"FI0L)&,AUCRYS@.1BO29 MS:B>W!Y>XC5$CE?&%H/&PKBF"((1T!:T+*[_5H"?W'G;%4VB*\HQ?)6EH7&< M,:]MSTB6=Q $1$#;%90B+Q>B7.FE_S]C]B2VSUFTOQ,\(D0]9956HU7?];>! MT6Z9>5.3FC0-"@V(L[?X!0@\5(%J=7RHS5@^+^:IA\95-C<>/2T>L3R M]LL M53.H- 9?!>\,>@'5 2C6K2G\[/TD 60 MQ)_W]^2!"/7>P9+LLL]R1T\=9Q@#8EV?O0UNCGDRUQL8!(1O=0N=ZJ6H7@%: MJ6?$RBK0[ZH2E-=B^_WR^J9K^4ENUIOD7RN<$KGEOU!+ P04 " U@')8 MU//HH5@' #55P %0 &%U9W@M,C R-# S,3A?<')E+GAM;,V<77/:.!2& M[W=F_X.7O28$:'>;--E.2D.':=ID0]KN[DU'V (TD25&D@/\^Y5L3/FPY),; MG^0B(>;5Q_L<6_:Q)5^\6Z4\>J)*,RDN6]V3TU9$12P3)F:7K:_C]M5X,!JU M(FV(2 B7@EZVA&R]^^O77R+[<_%;NQT-&>7)>?1!QNV1F,JWT1>2TO/H(Q54 M$2/5V^@;X9G;(H>,4Q4-9+K@U%#[1='P>?3ZI->=1.TVH-YO5"12?;T?;>N= M&[/0YYW.Q3&$5C@TQF=[6=KHZW?P4Q2\X$X_G[M>$:!I9 M7D*?KS2[;+EV-\TN^R=2S3J]T]-NYY_/-^-X3E/29L)QBVFK+.5JJ2K7/3L[ MZ^3?EM(CY6JB>-E&OU-V9UNS_98%]#L]T>Q=AKFXF\"O=?NY2U MW:9VM]?N=T]6.FF5\'."2G)Z3Z>1^VNCMVV59+.4)FSE M9Q7W8&TNZ0MJ=Y ML;FBT\N6%:UL[;U7I_WN&U?W[WLBLU[8'5,SMU^UHLY>NPM%-14FMWIC-^P5 MH2MC=R>:E!6Y]J$],\PX\69GZ49MMV=EJ6W+?BR4FXZ47>$RWFN=NPC( ZOE MWIQSUC0^F/; M*$^53'UT-B2DIZ.[H&P3S="\LNTGK@]#3F;5. \D0)Y=#*"5;K"(?J Z5FSA MN-2 W5,"^?90^59X:QAS>>S8O*N\(6'^.R/*4,77$-)'8B#LUYBP/0Z1>#\H(C1S M?"# C]5 XG^@7GAX/"(A'\\IYRZ%(P*TEU?I@=C_Q,3N]_D"P%\_N?.[/;7 MV>\4 >)_\U+P'[E%BL =54PF]I2N .R/Q$#J9YC4/0Y1>5^+!$I[*P7G/_BP M#^PAH1XR'1->]&AHM^DP[@HY%#E*SEEK$Q7[OY0H,/0=,10Y2AI:8[%AX(-, MJ;W.!$<5OQJ*'"4!K3/9,/-K89A9NWO^7[)T\O/&Z3[K8Q64,4K2Z3.%PK:\ MTR",>Y01XGNHA#)&R35#YE X#ZP?1?A()'3UB:Y#H(^D4-(H.6;0'@KJ.\52 MHM9C%MNK<(E#U*6@FRBQ*"D8BE M6LB=V\4#F=GC<3V027!(KRD(#0=*OOD,ZRA!N4H2BTMO_MPP0;NA4%3*P<^( M\ (0L/E"L/>>A[T'QXZ2A];:?"'8^\_#WH=C1\E%:VUB8A_8C[?J02X]3Z"] M8BARE%RTQB(F\/Q,>-U$8NT] M]'>^!L]@0QE6#VTTC/&[8L;V8"#3-!.;>S2>IV(>*10O2OH7M-X6H&.'5G*MT4,@HR9[?6,.$[Q1UD:;VLCN?Q^56&JC;Z=0W\H;T4.(H MN5Z]45SR(ZTSJI[+OZ(4- HH:1_4=-/C#(TS.^RMN[W)@ULQXQEECE10UB@I MG\]4PVR_R =%W%J]\3J=2.Y?'E(IA!)&2? "UAJ&O->/:KP'$BA8E,RNT@[2 MF'"]BN=$S*A_]D*U$@H8)=,+F4,;>V>@L7?VS+$7)>/SF4)B6\P-MT?4[82S M&?&O) L6 *^SP20>L-KT^KU\R8];Q:W2O!]#^Z$:NT<*!8ZS1#)DKVG46<(, M38HN#9D@(K8IU79=FR<[KR\%#0#.&DJ@:93;^]\IYY^$7(HQ)5H*FA27^J$[ M_-XBT"@@/D.LL8L2@F^29Y:2RB>"*L\QX)%"D2,^._38PYE[64QJWIY[BM=U MA(C[2D#!(SY$#)M%FI]FJ.LS>Z(?B"&;'H;X^TI ^2,^4 R;19L_KP;VQ#.3 MX6?F!T(H;<2IL)764""/4\+Y^TPS075P;#D00B$CSGFMM(8"^3JE:F8'M8]* M+LU\L[8S!-M3 H=<69KT"H._-7/=>3%^K<@^0HU^.T$B-B])K%>NQ'';B)% M<287"5$>ZB$]E#OJPDJ_T8;)WYHY5;O73WEG1C9O"TUZJ"\%C0)*N@HUC7-N MW5G)'SRU[NF@O!$3TRIC.&NFL@EG\9!+$KPNWY-!^2)FH16V4/"^)^)190L3 MK^^4C"EUCT_T]F@#)$3 "J A0-W>#>3UM\XWZY=[#:+?\#4$L#!!0 ( #6 T=:W?:N/([ MOT*7O7LW.2<\;" !DG(/)21EVSQN2+?M?LD1M@ UQG9E.X']]7=&ML$&DR=0 M2.G9;1I+&LU(\]+,6#[Z[W!@D#LF'&Z9[_Y0LOD_"#,U2^=F[]T?]7:CU?KC MO[744=^%;M#5=-ZE^ZYK5W.Y^_O[['TA:XE>3JE4*KDA]DG[G:K#Q'YJ/J_D MOIY]:FM]-J 9;CHN-34V'F1P\W8^?&P==^T(@\>ZXI-PDD)N!C2TZI,!T<[[ M.;\QUM5-[%KRN[IA5^Y8154Y> @/O\=XP'!>7P5Q!@K9U_=7GR;=W>3^DZXY M5U#3Z5IB0%W80H14RN35C+H? 9)QF!8#!+]G>];=HW#*F8(2PIG9G#BEV-RA MSGC%=3:UW.&I/>[B33.:)@PN%&Z3Q)DK;34C;T\$4Z^-!+QA=JMPP8"I M'OZK#YBIP__NB4%[-UUJ..P9D.H12$T3-F'4 %""&BU39\./;'23!Q5VL%\I MYXM/![O_'I;X^$:Y";2!#Q\>/0.$>M/N4\&<&_5&ZCX?AB.?/0/,,6)R&8 J MS" T#W;'TD?$<4<&>Y?N L]5B9*W77+-!]#CG-V3*VM S3W_P1[,+W@765OG M=^$PG3NV04=58EHFPS8^K"*;,@&\+W_ANLY,% 3\#7J=>P. H_E,/G2O4$_4 MG8LNI1T^L V&.B"8)@;9G\JQ/!',!)WDAE<#RB414Y0'FBGLR23UX%+B&HL"D& M'V$E _1[\@'C9YX433-3%]"0@V[!Q,PN*(R6S4]<2D]9GTSZ-7@+,R(S' MS+0&W'QDSD?78WK2!+!AMRL$NR:/R3(=AEJ\!X\TD!:F$B#]V #]*@]N/(,EKFD/6D*HTK9AY9Q+5M" M#,%G.I;K6H/@V3W7W3YBE_\]'1O=L000Y(]^;U#MEJB E6,97#\D06,(R6]7 M)NU(OM#Z_ST^N)\+W6<;62) MFB\5*ZLB915L_%PEXT.CGFN--8I:>E2A*-G2FJN,Q;%-2,Z&L'HHP2<75V/U?YR\.V^]YG>Z@#N)0YY M=(Z)'U[,@Q]>SGR<=L#'Z[L5Q:TH/J#!0XHVT/B 1;UJGE^GKIJ7%U?7&TG" MI2<2)JN;, HG.N:XA-W!M$$STW>K9-K6 M-:=LW:6,$#3]\$&RT;NLMYK?1M\_JKST+*/GQ^?1P+E5': /H&]?IZ,18,O, M)*,80R9J'=5T[8P*K4^4\A[!.;:&\I_OYLNB(1S'%@4K,,@]H.H!/^2P:XCUSQ@D27G[O5 MIS9V*O8YO;=/PST@/(C19M42AF3#AX+W^N[L8X-U(T_OF'"Y1HUP*P%2TMZ. MEZF@_KY@]3&MORLQ_=TR-4N =R4+#]HN^"D-/^'>L/0YZOSTCAX,E&]?A-9] MJ?^$-1&8%W*9+:P[U&QQ!^H)N$75?S%=.V8&O0<_["F*W]5GF.;9+!'N(29F<5^$>YDM]R\9:+7\K%UW38"G+ZFM2<#['TZ,?9 M]5G[^\>R\3Q=/LW2:1X:^6>8#PV6]=UP1PG M^/&)FTQ)]@*/6_^KM\KNT!SLO\H+3)@PZ@$>I&N*HJ3:G@LK0=JN8,R=XPCN MS21ZE$=(4Y-)H=+L(BB;31>FI #V ZHF@IL8=S7HR26H22=()O1"7 MPKH#3VQ.6.GOX^&UR=Z?M/3GT?7LL%(R4A'JE7RZU@"Q!<@FIW-(GZ$\4?8N M+4#'^)O;\\-IIO?WG2(:5O[S(K8S-F&4)B5=JP!E*\@T_FREN!,L!2:6;0%[ MRVUJ$#9DFN?R.\RA@(5CSB[9@64BN$Z+3);\;.K?G(V;9/W^\UM950X.G93+ M#&;W+9,14_K@>WC ,SST/ D5C(+@Z&RV5J 42"BJO#ITFR^3__O6T_^TO?OB MB^OBHG-$Q5!-UW;*Y?+N4[5*&*W_9($3?8DT/Q3..7VO]+]W+HQ/U@O1GIXF MBCH8T/W]2J98+I?>OA)YN0.ZWF6F#COK6K"Y \]PJ1C2H'Q>+A7-._A/#A(G<@(!&6*DJC1-4.ZIU1H6 A#RFJ M)5\UD*F:82P5WE$.2./DBJB%?!8Z[B;FJQ86%=LJ@E]#$;0M@VO 9&;O#.P@ M&$,C60M\NVY=_$,_J@>?7UZ\/$\+S.(050&EC5H. R%GY5XHTHZ@1 M%1![5V"L (KYK-]SJP.V.N 5.B!\7^]2,+3 >&.$?*4.O5QQT>W.+=XH?6Q\ M_WQVV^EU%JX+YN,2U0G[&Z\3@,Z,%B%4(AGW$9+T@YY1=SJ[3],0?M^MCMCJ MB%?HB&:RCF@YCL?$HYKBHVWTRWU'*]\M75/,8!35%P>_J+XHL$QQ1WN:O@CZ M/JPO7A_AP:+&)P6Q7O^*QPNG7:#C-S[!I?S@#Q-,CVW3^#57J=:#8!!LS8+# M.O)OM>A7V4"J^TIO<:[QR4U,C7 M7[4^T0SJ.(NK^%Z/VNT-VA!!]?"DV!X-.I:QX^QNM^-G;0>^\1D3#Q8:4-#: MX)K!DZ..R-4B"GZ!Q>1SJOX[L'H]88%51V5GB2KYK=%H-D].7N-X+GDIYY0@ M!29RI*@=J8J2_4@V*.OLM/B%VR]] V9ZGJAW6$[7T),,*@_;KJ7=[I%_Y[-X M:2'X=(+<4<-CQ,9[#OL/O>NU" %=Z?N7:XSI-,,4 X8)]*.O&I.YY:+T31/Z M"=<*Q@NY)39)E%4J\H7OKUL.6 &FU^ *SRMV"\4Y/,[,OP3@K^/>/>V5B^WO M!Z\J[T.]/UO9EX1'A%_4?!HLB*/3'W,X9J)QR!D5M\PEGSXUEANQ24RX+_5] M^O$E.B.B848?Y[\%@\SD*T13Z7;N$)@7SLV(8H^ Z;QW^WAZ MMC$%3QVBLRXW_;L,_$1QJ:RC7&NW.\N_!G$9 M2JB;FJ]6L#;4UU$DKJ/X3#50'S00,YCF@@8R+1D7\APF>P$!0#U&U[^+*EEDWE_\;>O\[DNOOOCP\#Q, MH@*C/CDLO""!6:B1?<$%-8N[]#ERJ7/B:_*JO2Y7VBP]M!E!'M$^A-$_/(S3 MPRA)@_2O9U?S@7L%HKN%%V+-;->^/"+9\=V="9L'EX[/S"\8OZ0>?$-GC[1,+;M' M* DO%"*1FP/(#EI@? U%A96 '>2UP/T#NR7??I!MRN'N'AA^,(=H^?%2MHGU M%P&;@,RG_()C3X#'\,.3M[9)?NER1X.>>*TD\9V.8Z8Q?!N#%!2)<"%+\%!N M8ZU[.!$,-<&OP)1.X-?XCX$?9V>'HTS7$R9W^DQ/43P%]7F'NZ12R2H2!UEF M'5(.&,!ACL&A##RH\4=-%GP&^CFL\':8&A@BQ![?P] '?AXS8I@=,BL'(;7F=R#&YYRO,YWF!V)0S &IQUN^!-+ M5"A8?A^[/2!,!"3R*(4QL8C* RZ=)5U___J4X/V#I#KB5"2"$25.8COMY.]A MJH/9\K9'-I0RCV\Z,!=U"*@.P"&X!%*+(4,<#U0<#?!8XXC%$J\P7H:YKV3S M2C9BU.5[Q%@*XEO[0**<)9CX;8W7VZKQDG>IKWF]4X2=M^6+FU+VLK(;\A+E M9;;<*UBFRJ*O-@V8TT_\![?5K.J.Q'#K?^F[$!^XR+:27_1N'S-'$]R>N8YN M+>X)+$X89/%*^ &V !V#3]^EU1>HKR7:C5F47U5^,UMI(WJ='35?W%,+Y3VU M5-I=OA^0?)79PE8,CV KNH3M3=PA1XG_559&\VI>J92*>84-*Y6,,OD@R8NE3>X2IGJV4R 848>M-PF$S& MD:_OKSX1E_8QP@DIOAE4!6!&MSTZY)E9SWX\--FGY8?3*6JA^1" M^N!.%6<)@KF'Y"^LS5U=IC7IY+'BMXJBJQ2NSR'!#V%625W0#M<."=8A^FMX M;N'**+%L;#A*%@E$+UA]&^GB-=BCA>9W?O9=3^W6Z7G]^O/5$K\VO$8 M$/D\II]I_>%Q$:0 GIK12B@]TSUC1#3J8=)89NR"KR+ZF3@':(0&R__*5X?U MJ=$EG9%,(LL<4] !,[4>9J(D..JY?4L \OH:)X#>3,!V!=^&6[(>P4_;ZE6)[_0G;3?TT/M^Y).SXC3,=)Y)YA1606_.R07'9,\@I]RT M-*W/K5^0E;=AQ9^)/K*?1'C+@AN[AQN.?J//F?_!L$EYUX7\6H#8Z(#>&KPQ MLP:Q('5]3\!QS'[*>T1K]/'K94M#KF/I(Y#:7-\=&+7_ U!+ P04 " U M@')8P??3#QXL GJ@$ '@ &5A,#(P,3DU-# Q97@Y.2TQ7V%U9VUE9&EX M+FAT;>U]:W/BR)+H=R+X#W6]W1/N6$$C(5[M'L>Z;7>/[_1KVYX]>S[=$*@P MFA$2HX?=S*^_F5DE(9 P B,L;#;B[+A!E+(RLS*S\OG^MYLOGT^KE?>_79Y= MP'\9_M_[FZN;SY>G[]^*_\*W;^77[S]\N_@WN[[Y]^?+7X^&KA.\8VIC$K ; M:\Q]]I7?LQ_NV' 4\8'"KKEG#8_@A_#3[]'OQH9W:SGO6..$!?QG4#-LZQ;^ MZ5FWH^#H]/V'T\N?(ZMO!:S7JZOOWWX 0+YG+E$+W DM(__9=X/ ':<6'G G MX-[1Z2].WY^^S+_0.GPU=CWUT0P\>^^_0\&!=Y@Z9UM":V73- MOZTTQ+FVNCV,TG*+9/LS] -K.#TZO3[[RC[^./MZ?G5]_DU!? Q&3.TJN'>= M_3(V#7]TPB+\5BO'7PW?-/Y^Q\[^^/2_;Q1F,)L;)J#+Y[2$JE4K8\#"R&<8Z<'"#NM/<65]MC+RV\"V' O@AO,+__*Y=V<-!(P9PIFSBN;? ?#X ?&]X M)@$'GPVMP.A;MA5,V:UKV#[")*&Q -NW)$_$<_A5"X#%';?K6F+#DM[5"D=! MY..A *":C0;KPS+P>]=R GPSTWOUYFN ;63!@1P /WE6/T22P'=X' #9X8!. M%>P=091T!5 &<&99/_2,0Q 7DF!Z+@!CP\90F ! MCYKI0_61<[-O#/YB(SCB?0Y'@#L#@-^X10H#R>'XCWUD'I %Q)0(F#$8\$F MFT<6G)V/.KMR@.$-&W#BF:@?(ZD*FPQM(W"]*4.]B?P$[ R_!RY&Z4('XY8[ MP%NTKSO#LHV^3>QC%8."J[ M.GOGKC.P0S/!J4HL_O$ RA[0-YN0_('N![[L6)1>:T(QE%G#($Q II M!S_#\T0$!$EZCX]DVQ#N!"V%T$'* P\.0=4%B/@0F$V*AA&8OL"K<+J&%A*^ M6J%#C:\4-,05AJ T7?PAB&R4I "G17O$5QNT1DT*$_ID=J#GP(DL&44(#F0# M'S<&1P 4%YX8P2:S&R"@F$WZYN?OQQ?0.6IP>$E+]3<,]W@)IJ)3YT M)$8-9EH NH?ZDO;JXK]P^V)SH,;@>-'QCW\([^YS.*T<7XQ0 #O]!:) F(6P M<3_Y*: 0M@>'&0X^?0X;@O6K%3162$R1X2EX!J 86!,2JR V1_ +,FG@/=+" MN9T9]C-1*A2Q8&HV4[.S'?1!B*"2!M89$U-$-H6)YLH=]P,D[^SKKP LB3G) MV\PS+! W@,,!".FM'/3R*-EX_9NS#Y\OP>S[_/G[V<7%U==/OQXUCNC?U]_/ MSJ-_2QCZI%5 H]JV,?$YW'3D7R> /SJ-+IJ7J3O,XBXR01;8G(/D M: ^Q\&\\TD6AX.W-C[)QDK9]% HW13E9IICM:B]HN^>@Y&_Y"]KP@9V?\W:W MRE&SHZ_1C['G_#&P1^Y;^+(%V)J052//#/P\_7^'EN&@/S ;.!]1\Z M)EJBKO>.>;?]8ZVA*UJSJVBMUIL,/I#VJ=9]?70J P;^(G=&-NSK)>=E\;'Y MLV'S(1RT5TL6[;W.C-NHFM+N-I8"DO6&;%'P!+!WE4Y++0GH#ZZ\!'Z]M1;P MKTN )=C^-;("GB'-TF_[E(A+/"R0ERZ1 MHF<&#MJ*ED;#*O06 (>N-/1>P7!D\T@&,"U]-22O"T2&IBHMK5T"JJA-I9<' M&:4C2]'6Q[+S*EQU12,"8XS%<6A^,-JE ./]QV]?;^:N!T-C;-G3=ZO\JO2L M;_W#A6L3-5J#]2=@1N**IV5A>[U;3QF43T'M5CUE'.XUM;5>HUK9E-P[L@*^ M8D0&!$N!,OY85_1>RI.17NM-D3"TE%8OA_K?%(;-)R(4+M*6HGQSDK ME!H:L$0>:ZQXDX0U!RW@<+IKC_U M,6S4]1S&9L&D:)>!%,T='<'\.O',Q*@W-]GEAZN;BS-V[+A.[=/9V?="R=%4 MFHT<5[)"80"QW,EQ,HH7RSD04:R6;"F:6B F\JIJO5&@E"A42[ZE/)'39Y/V M\G]J-?;1XK;YCGTW;OD)+/)WR)T!6ONL5HOP?7'U/Q$@R61^5)&H&-/ M*;]Y>

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end XML 18 ea0201954-8k_augmedix_htm.xml IDEA: XBRL DOCUMENT 0001769804 2024-03-18 2024-03-18 iso4217:USD shares iso4217:USD shares false 0001769804 8-K 2024-03-18 AUGMEDIX, INC. DE 001-40890 83-3299164 111 Sutter Street Suite 1300 San Francisco CA 94104 (888) 669-4885 false false false false Common Stock, $0.0001 par value per share AUGX NASDAQ true false